Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers

Overview

Journal Gastroenterology Res

Specialty Gastroenterology

Date 2016 Dec 13

PMID 27942274

Citations 9

Authors

Cornelia Braicu

Claudia Burz

Ioana Berindan-Neagoe

Ovidiu Balacescu

Florin Graur

Victor Cristea

Alexandru Irimie

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies. Although many advances have been made in the clinical study of HCC, the prognosis remains poor. Despite the discoveries in cancer biology in respect with physiological and pathological factors in relation to prognosis, HCC remains still a fatal disease due to late diagnosis. For improving the outcomes of patients with HCC, it is important to identify the factors predisposing to patient death. In recent years, based on cellular and molecular biology techniques, many tumor markers related to invasion, metastasis, recurrence and survival have been explored. However, routine biomarkers for the prediction of HCC evolution and prognosis are available in small number and less specific. These reviews focus on the recent advances in HCC tumorigenesis, revealing those biomarkers with prognosis significance or can be used for early detection.

Citing Articles

CircUSP10 promotes liver cancer progression by regulating miR-211-5p/TCF12/EMT signaling pathway.

Chen X, Xu Y, Zhou Z, Zhao P, Zhou Z, Wang F Heliyon. 2023; 9(10):e20649.

PMID: 37829805 PMC: 10565698. DOI: 10.1016/j.heliyon.2023.e20649.

Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC).

Yang X, Liu Q, Zou J, Li Y, Xie X Cancer Manag Res. 2021; 13:5683-5698.

PMID: 34295189 PMC: 8290353. DOI: 10.2147/CMAR.S316588.

Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model.

Vanderborght B, De Muynck K, Lefere S, Geerts A, Degroote H, Verhelst X Oncotarget. 2021; 11(48):4504-4520.

PMID: 33400730 PMC: 7721613. DOI: 10.18632/oncotarget.27830.

Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma.

Vohra I, Attar B, Katiyar V, Palacios P, Randhawa T, Baig M J Gastrointest Cancer. 2020; 52(1):201-206.

PMID: 32128703 DOI: 10.1007/s12029-020-00373-4.

Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer.

Wang H, Lu Z, Zhao X J Hematol Oncol. 2019; 12(1):133.

PMID: 31815633 PMC: 6902437. DOI: 10.1186/s13045-019-0806-6.

References

Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H . Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol. 2006; 13(2):159-67. DOI: 10.1245/ASO.2006.11.035. View

Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K . Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis. 2008; 29(10):1901-10. DOI: 10.1093/carcin/bgn170. View

Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P . SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer. 2005; 117(3):506-9. DOI: 10.1002/ijc.21189. View

Marrero J, Lok A . Newer markers for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S113-9. DOI: 10.1053/j.gastro.2004.09.024. View

Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H . Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res. 2008; 7(9):3847-59. DOI: 10.1021/pr800153s. View

Mukherjee B, Ghosh S, Das T, Doloi M . Characterization of insulin-like-growth factor II (IGF II) mRNA positive hepatic altered foci and IGF II expression in hepatocellular carcinoma during diethylnitrosamine-induced hepatocarcinogenesis in rats. J Carcinog. 2005; 4:12. PMC: 1199609. DOI: 10.1186/1477-3163-4-12. View

Baek H, Lim S, Kitisin K, Jogunoori W, Tang Y, Marshall M . Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology. 2008; 48(4):1128-37. PMC: 2747753. DOI: 10.1002/hep.22460. View

Su P, Lee T, Lin P, Lee P, Jeng Y, Chen C . Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer. 2007; 121(6):1257-64. DOI: 10.1002/ijc.22849. View

Buhlmann S, Racek T, Schwarz A, Schaefer S, Putzer B . Molecular mechanism of p73-mediated regulation of hepatitis B virus core promoter/enhancer II: implications for hepatocarcinogenesis. J Mol Biol. 2008; 378(1):20-30. DOI: 10.1016/j.jmb.2008.02.021. View

10.

Wei Y, Tran Van Nhieu J, Prigent S, Srivatanakul P, Tiollais P, Buendia M . Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology. 2002; 36(3):692-701. DOI: 10.1053/jhep.2002.35342. View

11.

Naugler W, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy A . Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007; 317(5834):121-4. DOI: 10.1126/science.1140485. View

12.

Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakitani K . Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res. 2000; 60(5):1394-402. View

13.

Murakami H, SANDERSON N, Nagy P, Marino P, Merlino G, Thorgeirsson S . Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 1993; 53(8):1719-23. View

14.

Spinzi G, Paggi S . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(23):2497-8. DOI: 10.1056/NEJMc081780. View

15.

Levy L, Renard C, Wei Y, Buendia M . Genetic alterations and oncogenic pathways in hepatocellular carcinoma. Ann N Y Acad Sci. 2002; 963:21-36. DOI: 10.1111/j.1749-6632.2002.tb04091.x. View

16.

Claudio P, Russo G, Kumar C, Minimo C, Farina A, Tutton S . pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance. Clin Cancer Res. 2004; 10(10):3509-17. DOI: 10.1158/1078-0432.CCR-03-0662. View

17.

Yao D, Jiang D, Huang Z, Lu J, Tao Q, Yu Z . Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000; 88(4):761-9. View

18.

Munakata T, Liang Y, Kim S, McGivern D, Huibregtse J, Nomoto A . Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 2007; 3(9):1335-47. PMC: 2323300. DOI: 10.1371/journal.ppat.0030139. View

19.

Itoh T, SHIRO T, Seki T, Nakagawa T, Wakabayashi M, Inoue K . Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med. 2000; 6(2):137-42. View

20.

Cervello M, Montalto G . Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol. 2006; 12(32):5113-21. PMC: 4088007. DOI: 10.3748/wjg.v12.i32.5113. View